288 related articles for article (PubMed ID: 33026184)
1. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001.
Burns MA; Place AE; Stevenson KE; Gutiérrez A; Forrest S; Pikman Y; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Asselin BL; Athale UH; Clavell LA; Cole PD; Gennarini LM; Kahn JM; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2021 Jan; 68(1):e28719. PubMed ID: 33026184
[TBL] [Abstract][Full Text] [Related]
2. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.
Vrooman LM; Blonquist TM; Harris MH; Stevenson KE; Place AE; Hunt SK; O'Brien JE; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
Blood Adv; 2018 Jun; 2(12):1449-1458. PubMed ID: 29941458
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.
Tembhare PR; Sriram H; Khanka T; Chatterjee G; Panda D; Ghogale S; Badrinath Y; Deshpande N; Patkar NV; Narula G; Bagal B; Jain H; Sengar M; Khattry N; Banavali S; Gujral S; Subramanian PG
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439800
[TBL] [Abstract][Full Text] [Related]
4. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
5. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
[TBL] [Abstract][Full Text] [Related]
6. [Long-term outcome of childhood T-cell acute lymphoblastic leukemia treated with modified national protocol of childhood leukemia in China-acute lymphoblastic leukemia 2008].
Liao C; Shen DY; Xu XJ; Xu WQ; Zhang JY; Song H; Yang SL; Zhao FY; Shen HP; Tang YM
Zhonghua Er Ke Za Zhi; 2020 Sep; 58(9):758-763. PubMed ID: 32872717
[No Abstract] [Full Text] [Related]
7. Next-generation sequencing of PTEN mutations for monitoring minimal residual disease in T-cell acute lymphoblastic leukemia.
Germano G; Valsecchi MG; Buldini B; Cazzaniga G; Zanon C; Silvestri D; Te Kronnie G; Basso G; Paganin M
Pediatr Blood Cancer; 2020 Jan; 67(1):e28025. PubMed ID: 31571345
[TBL] [Abstract][Full Text] [Related]
8. MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231.
Hayashi RJ; Hermiston ML; Wood BL; Teachey DT; Devidas M; Chen Z; Annett RD; Asselin BL; August K; Cho S; Dunsmore KP; Freedman JL; Galardy PJ; Harker-Murray P; Horton TM; Jaju A; Lam A; Messinger YH; Miles RR; Okada M; Patel S; Schafer ES; Schechter T; Shimano KA; Singh N; Steele A; Sulis ML; Vargas SL; Winter SS; Wood C; Zweidler-McKay PA; Loh ML; Hunger SP; Raetz EA; Bollard CM; Allen CE
Blood; 2024 May; 143(20):2053-2058. PubMed ID: 38457359
[TBL] [Abstract][Full Text] [Related]
9. [Clinical Features and Prognosis of Acute T-cell Lymphoblastic Leukemia in Children--Multi-Center Data Analysis in Fujian].
Wu CP; Zheng YZ; Li J; Wen H; Weng KZ; Zhuang SQ; Wu XG; Hua XL; Zheng H; Chen ZS; LE SH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):6-13. PubMed ID: 38387892
[TBL] [Abstract][Full Text] [Related]
10. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials.
Eckert C; Parker C; Moorman AV; Irving JA; Kirschner-Schwabe R; Groeneveld-Krentz S; Révész T; Hoogerbrugge P; Hancock J; Sutton R; Henze G; Chen-Santel C; Attarbaschi A; Bourquin JP; Sramkova L; Zimmermann M; Krishnan S; von Stackelberg A; Saha V
Eur J Cancer; 2021 Jul; 151():175-189. PubMed ID: 34010787
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study.
Wood BL; Devidas M; Summers RJ; Chen Z; Asselin B; Rabin KR; Zweidler-McKay PA; Winick NJ; Borowitz MJ; Carroll WL; Raetz EA; Loh ML; Hunger SP; Dunsmore KP; Teachey DT; Winter SS
Blood; 2023 Dec; 142(24):2069-2078. PubMed ID: 37556734
[TBL] [Abstract][Full Text] [Related]
12. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols.
Taj MM; Moorman AV; Hamadeh L; Petit A; Asnafi V; Alby-Laurent F; Vora A; Mansour MR; Gale R; Chevret S; Moppett J; Baruchel A; Macintyre E
Leukemia; 2022 Jan; 36(1):263-266. PubMed ID: 34183766
[No Abstract] [Full Text] [Related]
14. Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome.
Taga T; Tanaka S; Hasegawa D; Terui K; Toki T; Iwamoto S; Hiramatsu H; Miyamura T; Hashii Y; Moritake H; Nakayama H; Takahashi H; Shimada A; Taki T; Ito E; Hama A; Ito M; Koh K; Hasegawa D; Saito AM; Adachi S; Tomizawa D
Leukemia; 2021 Sep; 35(9):2508-2516. PubMed ID: 33589754
[TBL] [Abstract][Full Text] [Related]
15. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
[TBL] [Abstract][Full Text] [Related]
16. Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
Ratei R; Schabath R; Karawajew L; Zimmermann M; Möricke A; Schrappe M; Ludwig WD
Klin Padiatr; 2013 May; 225 Suppl 1():S34-9. PubMed ID: 23700065
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia.
Modvig S; Madsen HO; Siitonen SM; Rosthøj S; Tierens A; Juvonen V; Osnes LTN; Vålerhaugen H; Hultdin M; Thörn I; Matuzeviciene R; Stoskus M; Marincevic M; Fogelstrand L; Lilleorg A; Toft N; Jónsson OG; Pruunsild K; Vaitkeviciene G; Vettenranta K; Lund B; Abrahamsson J; Schmiegelow K; Marquart HV
Leukemia; 2019 Jun; 33(6):1324-1336. PubMed ID: 30552401
[TBL] [Abstract][Full Text] [Related]
18. Early T-cell precursor acute lymphoblastic leukemia and other subtypes: a retrospective case report from a single pediatric center in China.
Liu X; Zou Y; Zhang L; Chen X; Yang W; Guo Y; Chen Y; Zhang Y; Zhu X
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2775-2788. PubMed ID: 33651142
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of minimal residual disease in young adults with standard-risk/Ph-negative precursor B-acute lymphoblastic leukemia: results of prospective study.
Salah-Eldin M; Abousamra NK; Azzam H
Med Oncol; 2014 May; 31(5):938. PubMed ID: 24692146
[TBL] [Abstract][Full Text] [Related]
20. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience.
Goldberg JM; Silverman LB; Levy DE; Dalton VK; Gelber RD; Lehmann L; Cohen HJ; Sallan SE; Asselin BL
J Clin Oncol; 2003 Oct; 21(19):3616-22. PubMed ID: 14512392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
